About Vancoplus

Vancoplus is a novel antibiotic combination of a third generation cephalosporin ceftriaxone and a glycopeptide antibiotic vancomycin available as dry powder for reconstitution for intravenous administration. It is a synergistic antimicrobial combination with marked in vitro activity against broad spectrum Gram-positive and Gram-negative bacteria.


Vancoplus is supplied as a sterile dry powder in glass vial and comes in a unit carton pack containing one vial of dry powder for injection, solvent for reconstitution and package insert. Vancoplus is available in 1.5g and 3 g strength.


Vancoplus is indicated for the treatment of serious or severe infections caused by susceptible strains of Gram-positive (including methicillin-resistant strains) and Gram-negative pathogens.

Complicated skin and skin-structure infections (including cellulitis, myositis and necrotizing fasciitis) caused by:
  • Staphylococcus aureus including MRSA
  • Staphylococcus epidermidis
  • Streptococcus pyogenes
  • Viridans group streptococci
  • Escherichia coli
  • Enterobacter cloacae
  • Klebsiella oxytoca
  • Klebsiella pneumoniae
  • Proteus mirabilis
  • Morganella morganii
  • Serratia marcescens
  • Bacteroides fragilis
  • Peptostreptococcus species.
Empirical therapy in meningitis, central nervous system (CNS) infection like brain abscess, suppurative intra cranial infections and Epidural abscess caused by:-
  •  Haemophilus influenzae
  •  Neisseria meningitidis
  •  Streptococcus pneumoniae
  •  Staphylococcus epidermidis
  •  Escherichia coli

Prophylaxis of shunt infections:-

  • Staphylococcus aureus including MRSA
  • Acinetobacter spp
  •  Staphylococcus epidermidis


Prescribing Information

Prescribing Information